14.3 Pediatric Transfusion Medicine, Component Therapy & Massive Transfusion Protocols (MTP)
Key Takeaways
Use age, indication, component characteristics and weight to select a transfusion dose. Check the actual response because product and patient factors affect the increment.
Activate the pediatric hemorrhage protocol early for life-threatening bleeding. Give blood, prevent heat loss and pursue source control while monitoring perfusion and coagulation.
Use viscoelastic testing as an adjunct during hemorrhage. Consider early tranexamic acid in traumatic hemorrhagic shock under the pediatric protocol.
Follow ionized calcium and potassium during rapid transfusion. Treat symptomatic hypocalcemia promptly and manage cardiotoxic hyperkalemia when present.
Stop a suspected pulmonary transfusion reaction, stabilize the child and call the transfusion service. Assess for hydrostatic overload in TACO and acute permeability edema in TRALI.
Pediatric Blood Components and Massive Hemorrhage
Quick Answer: For stable anemia, use a population-specific red cell threshold and prescribe the volume for the child and product. For life-threatening bleeding, activate the pediatric hemorrhage protocol early, give blood and pursue source control. Follow perfusion, coagulation, temperature, ionized calcium and potassium. New respiratory distress during transfusion calls for stopping the component, supporting the child and alerting the transfusion service.
Select the Component and Calculate the Volume
Match the component to the deficit, bleeding risk and cause. Use the local blood bank's component characteristics and age-specific policies. For a routine transfusion, verify patient and product identification, use a compatible component, prescribe the volume in mL and reassess response before ordering more. Ongoing blood loss, hemolysis, dilution, platelet consumption and variable product concentration affect the measured increment. AABB Circular, pediatric dosing table
| Component | Pediatric example from the U.S. Circular | Expected response and caveats |
|---|---|---|
| Red cells (RBCs) | 10–15 mL/kg for common additive-solution products | Approximately 2 g/dL rise in hemoglobin for the example product and dose. More concentrated products can give a different increment. |
| Platelets | 5–10 mL/kg in the pediatric dosing table. Confirm the product and aliquot size. | In ideal recovery, the table estimates a 50,000–100,000/µL increase. Sepsis, consumption and alloimmune refractoriness can blunt the increment. |
| Plasma | 10–15 mL/kg to replace multiple soluble factors when indicated | Estimated 15–20% rise in factor level under ideal recovery. A mildly prolonged INR alone is a poor guide to benefit. |
| Cryoprecipitate | 2–3 mL/kg or 1–2 single-donor units per 10 kg in the U.S. pediatric table. Confirm the actual fibrinogen content and volume. | Estimated 60–100 mg/dL fibrinogen rise in that table. The U.S. Circular describes an average of at least 150 mg fibrinogen and 80 IU factor VIII per unit. Higher volume-per-kg doses may appear in protocols for different products. |
Worked volume example. For a 12-kg child, a selected 10 mL/kg RBC dose is 120 mL. If separately indicated, 10 mL/kg of platelets is 120 mL, 15 mL/kg of plasma is 180 mL, and 3 mL/kg of a cryoprecipitate product dosed by volume is 36 mL. The chart shows these independent calculations. They are not a combined order or a hemorrhage pack. Check the relevant post-transfusion hemoglobin, count or coagulation result. AABB Circular · Example of different component sizes and volumes
Indication-specific decisions
- RBCs: TRIPICU compared thresholds of 7 and 9.5 g/dL in stable critically ill children. AABB recommends considering transfusion below 7 g/dL for hemodynamically stable critically ill children or those at risk of critical illness without hemoglobinopathy, cyanotic heart disease or severe hypoxemia. For stable congenital heart disease, its conditional thresholds are 7 g/dL after biventricular repair, 9 g/dL with single-ventricle palliation and 7–9 g/dL for uncorrected disease. Use disease-specific guidance for neonates and sickle cell disease. Unstable nonhemorrhagic shock has no single pediatric TAXI hemoglobin trigger. A central venous oxygen saturation below 70% alone does not establish a transfusion indication. Active hemorrhagic shock follows a resuscitation protocol. TRIPICU trial · AABB RBC guideline · Pediatric TAXI shock guidance
- Platelets: The 2025 AABB/ICTMG guideline uses below 10,000/µL in nonbleeding hypoproliferative thrombocytopenia during chemotherapy or allogeneic stem cell transplant, and below 25,000/µL in neonatal consumptive thrombocytopenia without major bleeding. For patients undergoing lumbar puncture it recommends transfusion below 20,000/µL. The adult compressible-site central line recommendation does not establish a pediatric threshold. Consider bleeding severity, site, platelet function, coagulopathy and procedural risk in active bleeding, DIC, intracranial hemorrhage and surgery. Consult the pediatric team for context-specific targets. AABB/ICTMG platelet guideline · PlaNeT-2 trial · TAXI-CAB
- Plasma and fibrinogen: Use plasma for clinically significant bleeding with multiple coagulation factor deficits, or under the hemorrhage protocol. Plasma can serve as replacement during therapeutic plasma exchange for immune TTP. Select a specific factor product when indicated and available. Avoid plasma as a volume expander or simply to normalize INR in pediatric acute liver failure. In bleeding with documented hypofibrinogenemia, consider cryoprecipitate or fibrinogen concentrate under the applicable protocol. Choose the target for the specific cause and site of bleeding. AABB Circular · TAXI-CAB · NASPGHAN acute liver failure
Requesting modified products
Leukoreduction lowers the risk of febrile reactions, HLA alloimmunization and transfusion-transmitted CMV. For selected high-risk recipients, consult local requirements for CMV-seronegative components. Irradiation of cellular products prevents proliferation of donor T cells and is used when indicated for prevention of transfusion-associated graft-versus-host disease, for example for transfusion from a blood relative or in selected severe T-cell immunodeficiencies. Washing reduces residual plasma and can help when severe allergic reactions recur. IgA deficiency alone does not establish a need for washed products. Discuss severe prior reactions, anti-IgA, and requirements for exchange, transplant or ECMO with the blood bank. AABB Circular · AABB irradiation guidance
Life-Threatening Hemorrhage
Activate the local protocol for shock with suspected ongoing major hemorrhage or anticipated rapid transfusion. Estimated blood volume varies with age. Using a planning estimate of 70 mL/kg in an older child, 12 kg corresponds to about 840 mL of circulating blood. This estimate helps gauge the scale of loss. Activate based on physiology and projected need before a retrospective volume definition is met. Pediatric blood-volume guidance Request emergency-release blood through the blood bank and pursue operative, radiologic or other source control. Pediatric trauma consensus favors early blood and considers low-titer group O whole blood where available. For component therapy, pediatric TAXI-CAB supports considering initial RBC:plasma:platelets of 2:1:1 to 1:1:1. The pediatric trauma consensus suggests a high plasma:RBC ratio and high platelet:RBC ratio by volume. Use the local pack, product definitions and weight bands. Transition to targeted replacement as bleeding and physiology permit. Pediatric trauma consensus · TAXI-CAB trauma guidance · 2025 AHA/AAP PALS
Prevent heat loss, use a blood warmer as appropriate and restore perfusion. Hypothermia, acidosis and coagulopathy reinforce each other. Follow bleeding, hemodynamics, acid–base status, temperature, platelet count, fibrinogen and coagulation. Repeat ionized calcium and potassium during rapid transfusion. Citrate binds ionized calcium, and severe hypocalcemia can contribute to hypotension, QT prolongation and impaired clot formation. Treat symptomatic or marked hypocalcemia promptly with IV calcium under the pediatric protocol and reassess with ECG and repeat levels. As a named example, the McMaster pediatric hemorrhage protocol uses 20 mg/kg calcium chloride (max 1 g) or 60 mg/kg calcium gluconate (max 3 g). At 100 mg/mL these correspond to 0.2 or 0.6 mL/kg respectively. Check formulation, access and rate. Calcium chloride poses greater tissue injury risk with extravasation. Timing and repeat doses depend on the local protocol and measured response. McMaster pediatric hemorrhage card · EIIC pediatric MTP examples
Stored RBCs release potassium into the supernatant, and rapid infusion can cause abrupt hyperkalemia. Young age, rapid large-volume delivery, high baseline potassium and some processing methods increase concern. Obtain ECG and potassium promptly for new conduction changes. With cardiotoxic hyperkalemia, use IV calcium for membrane stabilization and institute potassium shifting and removal as indicated. Discuss selected risk-reduction products with transfusion medicine, especially for neonatal exchange or circuit priming. Avoid delaying lifesaving blood to source a special product in an emergency. Pediatric multicenter hyperkalemia study · Pediatric hyperkalemia pathway
Viscoelastic testing and tranexamic acid
Use TEG or ROTEM as an adjunct to clinical findings and conventional tests. Read the reference interval for the reagent and device. Several abnormalities can coexist.
| Clot phase | TEG / ROTEM example | Interpretation during bleeding |
|---|---|---|
| Initiation | R / CT | Prolongation can reflect reduced factor activity or anticoagulant effect. Assess cause before replacing factors. |
| Propagation | K and alpha angle / CFT and alpha angle | Slow clot growth can involve impaired fibrin formation and platelet contribution. Check fibrinogen and a fibrin-specific channel if available. |
| Strength | MA / MCF | Weak clot strength can reflect platelet, fibrinogen or combined deficits. Correlate with the platelet count and fibrin-specific results. |
| Lysis | LY30 / maximum lysis | Increased lysis can indicate accelerated clot breakdown. A single lysis result does not determine TXA use. |
Tranexamic acid limits plasminogen binding to fibrin and slows clot breakdown. In pediatric traumatic hemorrhagic shock, the consensus conditionally supports considering TXA within three hours of injury under the local regimen while resuscitation and source control proceed. Evidence is insufficient for an isolated LY30 trigger or for waiting on a lysis result before deciding. TIC-TOC demonstrated trial feasibility. A pediatric efficacy benefit and a single preferred regimen remain unestablished. Pediatric trauma consensus · TIC-TOC trial
Acute Respiratory Deterioration During or After Transfusion
Stop the suspected component, support airway, oxygenation and perfusion, verify identifiers and notify the transfusion service. Follow the reaction workup. Fever and shock also warrant consideration of bacterial contamination, hemolysis and concurrent sepsis. A lung reaction may overlap with other diagnoses.
| Finding | TACO | TRALI |
|---|---|---|
| Timing and mechanism | Hydrostatic edema and/or respiratory compromise during or up to 12 hours after transfusion. U.S. surveillance requires a combination of findings supporting overload. | Acute hypoxemia and bilateral pulmonary edema during or within 6 hours of transfusion. Permeability edema predominates. Donor antibody detection is unnecessary for the clinical diagnosis. |
| Supporting data | Fluid balance, cardiovascular changes, imaging or echocardiography suggesting elevated filling pressure and response to diuresis. BNP/NT-proBNP may support overload but is less specific in critical illness. | Hypoxemia such as room-air SpO₂ below 90%, bilateral edema and no substantial hydrostatic contribution. Fever or hypotension can occur. Their presence or absence is insufficient for diagnosis. |
| Initial support | Oxygen or positive-pressure support as needed. Treat overload with diuresis when perfusion permits. | Oxygen and lung-protective ventilation as needed. Support hemodynamics and avoid reflexive diuresis in a hypotensive child without overload. |
The international consensus describes TRALI type I without an ARDS risk factor and type II with an ARDS risk factor or mild ARDS and stable respiratory status during the 12 hours before transfusion. If the child was already deteriorating from the ARDS risk factor, evaluate for ARDS. The 2026 CDC NHSN surveillance protocol uses its own reporting criteria, including no evidence of acute lung injury before transfusion for definitive TRALI. Notify the blood bank early even when TRALI and TACO cannot yet be distinguished. TRALI consensus · 2026 CDC hemovigilance · AABB TACO bulletin, March 2026
A 25-kg child with hemorrhagic shock is receiving rapid blood component resuscitation. Hypotension worsens and the QTc lengthens. Point-of-care ionized calcium is 0.68 mmol/L and potassium is 4.5 mmol/L. Central access is available. The pediatric protocol uses calcium chloride 20 mg/kg from a 100 mg/mL preparation, up to 1 g per dose. What finding and immediate intervention fit?
Treat presumed potassium toxicity with insulin and dextrose based on the ECG.
Give platelet concentrate to correct hypotension and prolongation of the QTc.
Treat symptomatic citrate-associated hypocalcemia with 500 mg (5 mL) calcium chloride through the central line with monitoring.
Defer calcium until a fixed transfusion volume is reached, then repeat the electrolyte panel.
A 12-year-old with ongoing hemorrhagic shock from blunt liver and spleen trauma is undergoing damage control surgery two hours after injury. The pediatric hemorrhage protocol is active, and the child has not received TXA. TEG shows R-time 14.2 minutes (local reference 5–10), LY30 11.8% (reference 0–3%) and K-time, alpha angle and maximum amplitude within the assay reference ranges. Which interpretation and response are most appropriate?
Give cryoprecipitate and platelets solely because LY30 is elevated.
Stop hemostatic resuscitation and give protamine solely because R-time is prolonged.
Treat an isolated low fibrinogen level as established and delay hemorrhage control until repeat TEG.
Evaluate delayed clot initiation for factor replacement and consider early TXA under the pediatric hemorrhage protocol while continuing source control.
A 5-year-old develops abrupt dyspnea, hypoxemia (SpO₂ 82% on room air), fever and hypotension during a red cell transfusion. The child had stable respiratory status beforehand. Imaging shows new bilateral pulmonary edema. Fluid balance and echocardiography give no evidence of overload or elevated left-sided filling pressures. Which working diagnosis and initial response best fit?
Suspect TRALI. Stop the transfusion, support oxygenation and perfusion, and notify the blood bank for urgent reaction evaluation.
Treat presumed TACO with diuresis and continue the red cells at a reduced rate.
Treat a febrile nonhemolytic reaction with acetaminophen alone and restart the unit after the fever improves.
Treat this as an isolated allergic reaction with an antihistamine and defer evaluating the new pulmonary edema.
Sections you finish are checked off in the contents.